Prostatilen: smooth-muscle use claims — RU2058780C1
В.Х. Хавинсон, С.В. Серый, А.Л. Кожемякин, Р.И. Валеев · 1996 · RU2058780C1 · patent family 20132424
Published 1996-04-27.
Reported patent results
Reported findings
Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.
Patent reports include a 23-patient incontinence series and a separate prostate-adenoma comparison: 28 adjunctively treated versus 52 symptomatic-care patients.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Favorable conservative-treatment outcome | 15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic care | Patent-defined decision about unscheduled surgery · After inpatient conservative care |
| Residual urine ≤100 mL subgroup | 11/11 favorable outcomes versus 7/19 in controls | Small, potentially selected subgroups |
| Incontinence series | Near-complete cessation of involuntary urination in 17/23; sphincter-tone normalization in 15/23 | Separate uncontrolled series, not part of the 28-versus-52 comparison |
Concurrent treatment, nonrandom allocation and short-term clinical decisions prevent a reliable comparative efficacy estimate. Separate cohorts must not be combined into one response rate.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The patent describes uses of Prostatilen involving prostate, bladder or venous smooth-muscle function.
The preparation is a tissue-derived complex; these claims do not establish equivalence to a defined synthetic prostate peptide.
- Publication
- RU2058780C1 ↗ · 1996-04-27
- Earliest priority / filing
- 1992-11-17 / 1992-11-17
- Original applicant / assignee
- Совместное русско-американское акционерное общество закрытого типа "Неофарм"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20132424 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent showing tonic action on the vein, bladder and prostate gland smooth muscle
Inventors: В.Х. Хавинсон; С.В. Серый; А.Л. Кожемякин; Р.И. Валеев.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The preparation is a tissue-derived complex; these claims do not establish equivalence to a defined synthetic prostate peptide.
- Concurrent treatment, nonrandom allocation and short-term clinical decisions prevent a reliable comparative efficacy estimate. Separate cohorts must not be combined into one response rate.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20132424. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: В.Х. Хавинсон, С.В. Серый, А.Л. Кожемякин, Р.И. Валеев. Prostatilen: smooth-muscle use claims — RU2058780C1 RU2058780C1 · patent family 20132424 1996.
Molekul research summary: https://molekul.io/research/patent-ru2058780c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry